SIGA250117C22050
- 0.48
- 0.000.00%
SIGA Technologies Newsroom
SIGA Technologies Says Japan's Pharmaceutical Regulator Approves Its Antiviral Treatment for Smallpox, MPox, Cowpox
Express News | SIGA Technologies Inc - Japan Biotechno Pharma to Supply Tepoxx to National Stockpile
Express News | Tepoxx (Tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses
Arm Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
SIGA Technologies Shares Are Trading Lower After Interim Results From the STOMP Study Showed That Tecovirimat Did Not Improve the Time to Lesion Resolution Compared to Placebo in Adults With Mild to Moderate Clade II Mpox.
Express News | SIGA Technologies Inc - Efficacy in Severe Mpox Patients Not Assessed in Study
Express News | SIGA Technologies Inc - Study Stopped Enrolling Patients in All Study Arms
Express News | Interim Results From Stomp Study of Siga’s Tecovirimat in Treatment of Mpox Announced
Express News | Nih: Data Safety and Monitoring Board Recommended Stopping Further Enrollment of Participants Who Were Being Randomized to Tecovirimat or Placebo
'NIH Study Finds Tecovirimat Was Safe but Did Not Improve Mpox Resolution Or Pain'
Siga Technologies (SIGA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Why SIGA Technologies (SIGA) Is One of the Most Profitable Pharmaceutical Stocks Right Now?
Are Investors Undervaluing Siga Technologies (SIGA) Right Now?
First Mpox Case Linked to African Outbreak Reported in U.S.
US Manufacturing Index Rises To 43, Highest Since 2020
SIGA Technologies' (NASDAQ:SIGA) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth
SIGA Technologies Reports Strong Earnings and Growth
SIGA Technologies, Inc. (SIGA) Q3 2024 Earnings Call Transcript Summary
SIGA Technologies | 10-Q: Q3 2024 Earnings Report